Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 4/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 9/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992666 | 1.00 | RHEB (0.45) | RHEBAHRHTR1BTRPA1HTR1A | |
| SCHEMBL11304563 | 0.83 | RHEB (0.50) | RHEBAHRHTR1BTRPA1HTR1A | |
| SCHEMBL19645305 | 0.79 | RHEB (0.38) | RHEBAHRTRPA1 | |
| SCHEMBL5957996 | 0.79 | SLC22A6 (0.49) | AHRHTR1BHTR1AADRB1CYP3A4 | |
| SCHEMBL30681623 | 0.79 | AHR (0.57) | RHEBAHRHTR1BTRPA1HTR1A | |
| SCHEMBL3373757 | 0.78 | HTR1A (0.43) | RHEBHTR1BTRPA1HTR1AADRB2 | |
| SCHEMBL31190636 | 0.76 | IDO1 (0.50) | CYP1A2CYP3A4LMNADRD4DRD3 | |
| SCHEMBL3801229 | 0.76 | RHEB (0.54) | RHEBAHRHTR1BTRPA1HTR1A | |
| SCHEMBL3870264 | 0.75 | BCHE (0.48) | AHRHTR1BHTR1AHTR2C | |
| SCHEMBL2087774 | 0.75 | HTR1B (0.51) | RHEBAHRHTR1BTRPA1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022232931-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| EP-1757585-B1 | Anionically substituted 7-Nitroindoline derivatives and their uses | MEDICAL RES COUNCIL (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7737169-B2 | Anionically substituted 7-nitroindoline derivatives and their uses | MEDICAL RESEARCH COUNCIL (GB) | 2010-06-15 | — | — | US | disclosed |
| US-7737169-B2 | Anionically substituted 7-nitroindoline derivatives and their uses | MEDICAL RESEARCH COUNCIL (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-1781608-B1 | INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-6060492-A | SIDE EFFECT REDUCTION | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-5977154-A | OBESITY, DIABETES | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0950661-A1 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5939443-A | ANTIDIABETIC AGENTS AND TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| US-5840738-A | Selective β-3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5808080-A | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5786356-A | TREATING TYPE II DIABETES, OBESITY | ELI LILLY AND COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997010825-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0764640-A1 | Selective beta3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1997-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | RHEB 1569/4885AHR 159/4885HTR1B 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.